Expert panel recommendations: Based on the findings of SOLAR‐1 and BYLieve studies, combination therapy of alpelisib and fulvestrant may be used in patients with PIK3CA‐mutated, HR‐positive/HER2‐negative breast cancer who experienced disease progression during or after endocrine therapy‐based regimens. Here, ERBB2 is linked to breast carcinoma.